Literature DB >> 35534352

Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.

Vinai Gondi1, Glenn Bauman2, Lisa Bradfield3, Stuart H Burri4, Alvin R Cabrera5, Danielle A Cunningham6, Bree R Eaton7, Jona A Hattangadi-Gluth8, Michelle M Kim9, Rupesh Kotecha10, Lianne Kraemer11, Jing Li12, Seema Nagpal13, Chad G Rusthoven14, John H Suh15, Wolfgang A Tomé16, Tony J C Wang17, Alexandra S Zimmer18, Mateo Ziu19, Paul D Brown6.   

Abstract

PURPOSE: This guideline provides updated evidence-based recommendations addressing recent developments in the management of patients with brain metastases, including advanced radiation therapy techniques such as stereotactic radiosurgery (SRS) and hippocampal avoidance whole brain radiation therapy and the emergence of systemic therapies with central nervous system activity.
METHODS: The American Society for Radiation Oncology convened a task force to address 4 key questions focused on the radiotherapeutic management of intact and resected brain metastases from nonhematologic solid tumors. The guideline is based on a systematic review provided by the Agency for Healthcare Research and Quality. Recommendations were created using a predefined consensus-building methodology and system for grading evidence quality and recommendation strength.
RESULTS: Strong recommendations are made for SRS for patients with limited brain metastases and Eastern Cooperative Oncology Group performance status 0 to 2. Multidisciplinary discussion with neurosurgery is conditionally recommended to consider surgical resection for all tumors causing mass effect and/or that are greater than 4 cm. For patients with symptomatic brain metastases, upfront local therapy is strongly recommended. For patients with asymptomatic brain metastases eligible for central nervous system-active systemic therapy, multidisciplinary and patient-centered decision-making to determine whether local therapy may be safely deferred is conditionally recommended. For patients with resected brain metastases, SRS is strongly recommended to improve local control. For patients with favorable prognosis and brain metastases receiving whole brain radiation therapy, hippocampal avoidance and memantine are strongly recommended. For patients with poor prognosis, early introduction of palliative care for symptom management and caregiver support are strongly recommended.
CONCLUSIONS: The task force has proposed recommendations to inform best clinical practices on the use of radiation therapy for brain metastases with strong emphasis on multidisciplinary care.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2022        PMID: 35534352     DOI: 10.1016/j.prro.2022.02.003

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  4 in total

1.  Interfractional change of tumor volume during fractionated stereotactic radiotherapy using gamma knife for brain metastases.

Authors:  Mariko Kawashima; Atsuya Akabane; Ryuichi Noda; Masafumi Segawa; Sho Tsunoda; Tomohiro Inoue
Journal:  J Neurooncol       Date:  2022-07-09       Impact factor: 4.506

2.  Radiotherapy or systemic therapy versus combined therapy in patients with brain metastases: a propensity-score matched study.

Authors:  Yutaro Koide; Naoya Nagai; Risei Miyauchi; Tomoki Kitagawa; Takahiro Aoyama; Hidetoshi Shimizu; Hiroyuki Tachibana; Takeshi Kodaira
Journal:  J Neurooncol       Date:  2022-09-16       Impact factor: 4.506

3.  A Rare Case of Brain Metastases in an Elderly Patient With Primary Pancreatic Cancer.

Authors:  Sharad Rajpal; Hash B Taha; Lukas Kvascevicius; Sigita Burneikiene
Journal:  Cureus       Date:  2022-08-01

4.  Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1-4 brain metastases.

Authors:  Zhengting Chen; Lingli Zhou; Min Zhao; Ke Cao; Yanqing Li; Xiaoling Liu; Yu Hou; Lan Li; Li Wang; Li Chang; Mei Yang; Wenhui Li; Yaoxiong Xia
Journal:  BMC Cancer       Date:  2022-09-24       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.